Related Experiment Video
Updated: Aug 18, 2026

Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening
Published on: July 18, 2012
Pharmacokinetics of fluconazole in skin and nails
1Department of Dermatology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Abstract:
Two studies on the pharmacokinetics of fluconazole in skin and nails are reported here. In 1 study, 12 healthy volunteers received fluconazole 50 mg once daily for 12 days and 11 healthy volunteers received fluconazole 150 mg once weekly for 2 weeks. Fluconazole assays were performed on samples of serum, stratum corneum, dermis-epidermis, and eccrine sweat. In a second study, 36 patients with toenail onychomycosis received either fluconazole 150 mg once weekly or griseofulvin 1000 mg once daily for 12 months. Fluconazole assays were performed on nail clippings and serum samples from the patients receiving fluconazole. Tissue concentrations of fluconazole regularly exceeded plasma concentrations in these studies. In the skin study, the highest concentrations were achieved in stratum corneum, with accumulation occurring up to the end of dosing. Subjects who received 50 mg once daily had higher levels of fluconazole in stratum corneum, sweat, and epidermis-dermis than those subjects who received 150 mg once weekly. In the toenail study, fluconazole concentrations increased for the first 6 months, reaching levels much higher than serum concentrations (P < .001), with no significant difference between healthy and diseased nails.
Related Concept Videos
Non-Oral Extravascular Drug Absorption Routes
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more effectively...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Candidiasis
Antifungal Agents

